NYSEARCA:PSIL AdvisorShares Psychedelics ETF (PSIL) Price, Holdings, & News $16.28 +0.52 (+3.27%) As of 02:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartHoldingsOwnershipRatingsShort InterestBuy This Stock About AdvisorShares Psychedelics ETF (NYSEARCA:PSIL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PSIL alerts:Sign Up Key Stats Today's Range$15.80▼$16.3050-Day Range$13.42▼$17.2152-Week Range$7.14▼$17.41Volume10,408 shsAverage Volume12,004 shsMarket Capitalization$13.03 millionAssets Under Management$12.63 millionDividend Yield2.03%Net Expense Ratio0.99%Aggregate RatingBuy ETF Overview The AdvisorShares Psychedelics ETF (PSIL) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed to provide exposure to the emerging global psychedelics industry. PSIL was launched on Sep 15, 2021 and is managed by AdvisorShares. Read More AdvisorShares Psychedelics ETF ExpensesTypePSILTheme ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.60%0.57%0.56%0.51%0.53%Other Expenses2.35%0.57%0.56%0.59%0.56%Total Expense2.95%0.74%0.76%0.74%0.73%Fee Waiver-1.96%-0.76%-0.66%-0.71%-0.63%Net Expense0.99%0.60%0.63%0.58%0.60% Receive PSIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AdvisorShares Psychedelics ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address PSIL ETF News HeadlinesNo Trippin’: Trump Trade Pushes PSIL, VCAR HigherNovember 15, 2024 | finance.yahoo.comDRUG Enhances Buzz for Psilocybin, Psychedelic ETFsOctober 18, 2024 | finance.yahoo.comBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. August 21 at 2:00 AM | Crypto 101 Media (Ad)AdvisorShares Psychedelics ETF (ARCA:PSIL), Short Interest ReportSeptember 12, 2024 | benzinga.comAdvisorShares Announces Reverse Split of ETFAugust 30, 2024 | finance.yahoo.comAdvisorShares Psychedelics ETFFebruary 13, 2024 | thestreet.comSee More Headlines PSIL ETF - Frequently Asked Questions How have PSIL shares performed this year? AdvisorShares Psychedelics ETF's stock was trading at $10.98 at the beginning of 2025. Since then, PSIL shares have increased by 47.8% and is now trading at $16.2250. How do I buy shares of AdvisorShares Psychedelics ETF? Shares of PSIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AdvisorShares Psychedelics ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that AdvisorShares Psychedelics ETF investors own include Tilray Brands (TLRY), Bright Minds Biosciences (DRUG), Las Vegas Sands (LVS), NVIDIA (NVDA), Archer Aviation (ACHR), Blade Air Mobility (BLDE) and Blink Charging (BLNK). Fund Details IssuerAdvisorShares Fund NameAdvisorShares Psychedelics ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:PSIL Inception Date9/15/2021 Fund ManagerDan S. Ahrens WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkN/A CategoryStrategy FocusTheme Development LevelBlended Development RegionGlobal Number of Holdings28 Fund Statistics Assets Under Management$12.63 million Average Daily Volume$0.00 Discount/Premium0.09% Administrator, Advisor and Custodian AdministratorThe Bank of New York Mellon Corporation AdvisorAdvisorShares Investments, LLC CustodianThe Bank of New York Mellon Corporation DistributorForeside Fund Services, LLC Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerVirtu Financial Options OptionableOptionable Options Volume20 Put Options15 Call Options5 Short Interest55,800 shs Miscellaneous Outstanding Shares800,000Beta0.93 Creation Fee$500.00 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report Top 10 PSIL Holdingsatai Life Sciences (NASDAQ:ATAI)Holding Weight: 13.32%Mind Medicine (MindMed) (NASDAQ:MNMD)Holding Weight: 9.01%Quantum BioPharma Ltd.Holding Weight: 7.92%COMPASS Pathways (NASDAQ:CMPS)Holding Weight: 6.83%Cybin Inc.Holding Weight: 6.65%Alkermes (NASDAQ:ALKS)Holding Weight: 5.71%NRx Pharmaceuticals (NASDAQ:NRXP)Holding Weight: 5.34%Neuronetics (NASDAQ:STIM)Holding Weight: 5.19%GH Research (NASDAQ:GHRS)Holding Weight: 5.06%Neurocrine Biosciences (NASDAQ:NBIX)Holding Weight: 4.82%Full Holdings DetailsPSIL Sector ExposurePSIL Industry Exposure This page (NYSEARCA:PSIL) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AdvisorShares Psychedelics ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share AdvisorShares Psychedelics ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access